Abstract
Original citation: JCI Insight. 2020;5(9):e132747. https://doi.org/10.1172/jci.insight.132747
Citation for this corrigendum: JCI Insight. 2023;8(6):e169756. https://doi.org/10.1172/jci.insight.169756
The authors recently became aware that the Mito-FerroGreen (MFG) used in this study is not an Fe2+ chelator, but instead reduces Fe2+ via conversion to Fe3+. As MFG mediates reduction of Fe2+ and suppresses ferroptosis, the overall conclusions are not affected. For clarity, the authors have removed references to MFG-mediated chelation throughout, updated the Graphical Abstract, and renumbered the reference list to refer to Hirayama et al. (1) when first describing the use of MFG in the Results section. The text and Graphical Abstract have been updated in the HTML version and PDF. The Journal has also published an online version of the original article with the incorrect statements crossed out and the modified text printed in red (Supplemental File, Redaction).
The authors regret the errors.
Supplementary Material
Version 1. 03/22/2023
Electronic publication
Footnotes
See the related article at Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity.
References
- 1.Hirayama T, et al. A mitochondria-targeted fluorescent probe for selective detection of mitochondrial labile Fe(ii) Metallomics. 2018;10(6):794–801. doi: 10.1039/C8MT00049B. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.